Jennifer Barrett, Associate Editor

Patients who were more satisfied with the communication they received from cancer care providers often had better health outcomes at lower costs.

Researchers have developed a novel peptide drug that has the potential to reduce tumor growth and slow down the spread of cancer cells.

Treating patients’ stress and poor sleep may help reduce the risk of depression in multiple sclerosis.

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.

Organ transplant recipients who received infected kidneys were cured of hepatitis C after taking antiviral therapy following the procedure.

The guidelines fill an unmet clinical need for a standard care consensus on gestational trophoblastic neoplasia, a group of rare cancers that affect pregnant women.

Officials with the FDA have approved the first targeted treatment for adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, a rare and often fatal disease.

Patisiran (Onpattro, Alnylam Pharmaceuticals) is indicated for the treatment of adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR), a rare genetic disease.

In response to the CMS’ step therapy approach to lowering drug costs, many advocacy groups expressed concern that the move will harm patient access to treatments for chronic conditions.

Higher-than-recommended physical activity levels can help older adults avoid chronic diseases, disability, and cognitive decline for longer.

Drug costs in the United States are not consistently associated with their value or net health benefits.

Study offers insight into the evolution of global dissemination of hepatitis B virus genotypes D and A.

The FDA has approved updates to the labeling for hepatitis C virus (HCV) drug glecaprevir and pibrentasvir (Mavyret) to include new data from 2 clinical studies.

Officials with the FDA have approved a new treatment for 2 rare types of non-Hodgkin lymphoma of the skin, relapsed or refractory mycosis fungoides and Sézary syndrome, after at least 1 prior systemic therapy.

A healthy diet that includes physical activity and discourages alcohol consumption can significantly reduce overall cancer risk, as well as lower breast, prostate, and colorectal cancer risk.

The Affordable Care Act reduced financial strain for all low-income adults; however, the most significant reductions were seen in those living closest to the federal poverty line.

In its latest report, the Institute for Clinical and Economic Review (ICER) evaluated the efficacy and value of newer targeted agents that treat moderate-to-severe plaque psoriasis compared with non-targeted therapies.

Guselkumab and risankizumab were found to be superior to non-targeted therapies for the treatment of moderate-to-severe plaque psoriasis.

Silvestrol inhibited the replication of pathogens in both cell cultures and in a mouse model.

New research demonstrates continued virologic control in patients with HIV-1 following a switch to Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg [D/C/F/TAF]) regardless of prior treatment regimen

Clinical data demonstrate continued virologic response rates in patients with HIV switching to Symtuza from boosted protease inhibitor-based regimens.

Survey authors identified an unmet need for clinician engagement regarding financial concerns after breast cancer diagnosis.

HIV-associated cardiovascular disease is on the rise among individuals living with the virus, particularly in regions with limited resources.

Advancements in breast cancer treatment have improved survival rates, but financial hardships related to the cost of these lifesaving therapies can weigh heavily on patients.

Survey findings indicate that patients with breast cancer worry about financial hardships related to their treatment, yet many do not feel providers adequately address these concerns.

Interferon regulatory factor 2 binding protein-like gene is essential for neurological development and maintenance.

In a groundbreaking new study, researchers have identified a molecular pathway for stimulating the regeneration of new myelinating cells, and repairing the damage of debilitating neurological diseases.

Study finds that several multiple sclerosis drug candidates inhibit the same enzyme to stimulate myelin regeneration.

Officials with the FDA have approved risperidone (Perseris, Indivior) for extended-release injectable suspension for the treatment of schizophrenia in adults.